Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Michael R. Green, R. Eric Davis et al.|Nature Medicine|2020Cited by 593
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Neeraj Saini et al.|Nature Medicine|2023Cited by 226
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C. Pinnix, Loretta J. Nastoupil, Jillian R. Gunther et al.|Blood Advances|2020Cited by 224
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sattva S. Neelapu, Sairah Ahmed et al.|Blood|2021Cited by 213
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphomaPaolo Strati, Jason R. Westin, Sairah Ahmed et al.|Blood Advances|2020Cited by 195